<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><description>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 07 Feb 2021 11:16:54 +0800</pubDate><image><url>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</url><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>游方和尚专栏 | 大分子生物分析概论之十四： LBA定量分析双特异性生物药的挑战</title><link>https://mp.weixin.qq.com/s/kTkwKzg1YCJcsdSLpBZ5qQ</link><description></description><content:encoded><![CDATA[游方和尚专栏 | 大分子生物分析概论之十四： LBA定量分析双特异性生物药的挑战]]></content:encoded><pubDate>Sat, 06 Feb 2021 18:53:13 +0800</pubDate></item><item><title>2020年全球畅销药TOP20</title><link>https://mp.weixin.qq.com/s/8Y5Bh_0A1uejHF3-1Sck5w</link><description></description><content:encoded><![CDATA[2020年全球畅销药TOP20]]></content:encoded><pubDate>Sat, 06 Feb 2021 18:53:13 +0800</pubDate></item><item><title>最新进展！TG-Bio第二届免疫治疗技术大会4月申城亮相！</title><link>https://mp.weixin.qq.com/s/2UCDO2PUDPil9aQXhmhw5Q</link><description></description><content:encoded><![CDATA[最新进展！TG-Bio第二届免疫治疗技术大会4月申城亮相！]]></content:encoded><pubDate>Sat, 06 Feb 2021 18:53:13 +0800</pubDate></item><item><title>Nature：uPAR CAR-T开创抗衰老细胞治疗</title><link>https://mp.weixin.qq.com/s/mD1LBO3IUdf00HaN6IhcLg</link><description></description><content:encoded><![CDATA[Nature：uPAR CAR-T开创抗衰老细胞治疗]]></content:encoded><pubDate>Sat, 06 Feb 2021 09:13:07 +0800</pubDate></item><item><title>原FDA专家谈国内法规修订原则及中美双报发展趋势</title><link>https://mp.weixin.qq.com/s/yDh1KlkdEcEu-Pf-cfWyPw</link><description></description><content:encoded><![CDATA[原FDA专家谈国内法规修订原则及中美双报发展趋势]]></content:encoded><pubDate>Sat, 06 Feb 2021 09:13:07 +0800</pubDate></item><item><title>IL-36：炎症与肿瘤</title><link>https://mp.weixin.qq.com/s/I3ycKougpg_D-ElJlw6xQw</link><description></description><content:encoded><![CDATA[IL-36：炎症与肿瘤]]></content:encoded><pubDate>Sat, 06 Feb 2021 09:13:07 +0800</pubDate></item><item><title>ADC药物组织分布的影响因素</title><link>https://mp.weixin.qq.com/s/rz4-gzBj1QzDrowdMTwF_A</link><description></description><content:encoded><![CDATA[ADC药物组织分布的影响因素]]></content:encoded><pubDate>Thu, 04 Feb 2021 18:10:09 +0800</pubDate></item><item><title>到底应该打哪种新冠疫苗？</title><link>https://mp.weixin.qq.com/s/quSqO2Jz4V5XdP47ShBLlw</link><description></description><content:encoded><![CDATA[到底应该打哪种新冠疫苗？]]></content:encoded><pubDate>Thu, 04 Feb 2021 18:10:09 +0800</pubDate></item><item><title>爵士制药72亿美元收购大麻素药企GW Pharma</title><link>https://mp.weixin.qq.com/s/-SGhRGe4JNhKywujvbHYSg</link><description></description><content:encoded><![CDATA[爵士制药72亿美元收购大麻素药企GW Pharma]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:39:50 +0800</pubDate></item><item><title>三叶草生物新冠疫苗极具潜力</title><link>https://mp.weixin.qq.com/s/IZEOpZWpy3zGhhUvLfoGpg</link><description></description><content:encoded><![CDATA[三叶草生物新冠疫苗极具潜力]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:21:47 +0800</pubDate></item><item><title>崭露头角的HER2后浪​—ZW25临床研究进展</title><link>https://mp.weixin.qq.com/s/dGZosF-Rj17Xti-wjoT7tQ</link><description></description><content:encoded><![CDATA[崭露头角的HER2后浪​—ZW25临床研究进展]]></content:encoded><pubDate>Mon, 01 Feb 2021 19:14:16 +0800</pubDate></item><item><title>小靶点，大突破：一文掌握MET抑制剂研发现状</title><link>https://mp.weixin.qq.com/s/s1dyr2i6b07Tb63uLHRiaQ</link><description></description><content:encoded><![CDATA[小靶点，大突破：一文掌握MET抑制剂研发现状]]></content:encoded><pubDate>Mon, 01 Feb 2021 19:14:16 +0800</pubDate></item><item><title>胰岛素百年史</title><link>https://mp.weixin.qq.com/s/w0svmdleeWsXPmdYe8fSOw</link><description></description><content:encoded><![CDATA[胰岛素百年史]]></content:encoded><pubDate>Sun, 31 Jan 2021 17:38:54 +0800</pubDate></item><item><title>Science Advances：安全、有效的B7-H3×4-1BB双特异抗体及其机制研究</title><link>https://mp.weixin.qq.com/s/jpC6wRx8L9RvgieUb8QrVw</link><description></description><content:encoded><![CDATA[Science Advances：安全、有效的B7-H3×4-1BB双特异抗体及其机制研究]]></content:encoded><pubDate>Sat, 30 Jan 2021 20:07:35 +0800</pubDate></item><item><title>肿瘤免疫版ADC</title><link>https://mp.weixin.qq.com/s/jALulI9sA_XPwYiI4Sesog</link><description></description><content:encoded><![CDATA[肿瘤免疫版ADC]]></content:encoded><pubDate>Sat, 30 Jan 2021 20:07:35 +0800</pubDate></item><item><title>靶向肿瘤干细胞的药物开发靶点：CD44</title><link>https://mp.weixin.qq.com/s/eRSVzDrOwf0feQNfZH-bVg</link><description></description><content:encoded><![CDATA[靶向肿瘤干细胞的药物开发靶点：CD44]]></content:encoded><pubDate>Fri, 29 Jan 2021 23:52:16 +0800</pubDate></item><item><title>哪些精彩看点？｜2021TG-Bio第二届免疫治疗技术大会最新进展</title><link>https://mp.weixin.qq.com/s/nMU7GeX1L97JIezpqfKdDA</link><description></description><content:encoded><![CDATA[哪些精彩看点？｜2021TG-Bio第二届免疫治疗技术大会最新进展]]></content:encoded><pubDate>Fri, 29 Jan 2021 23:52:16 +0800</pubDate></item><item><title>RNA疫苗十年诞生史</title><link>https://mp.weixin.qq.com/s/uiUs8TelwtxTrz72LtRXng</link><description></description><content:encoded><![CDATA[RNA疫苗十年诞生史]]></content:encoded><pubDate>Fri, 29 Jan 2021 00:19:46 +0800</pubDate></item><item><title>2021中国免疫治疗新趋势</title><link>https://mp.weixin.qq.com/s/I7465XbWKfjV5ngC629nMA</link><description></description><content:encoded><![CDATA[2021中国免疫治疗新趋势]]></content:encoded><pubDate>Fri, 29 Jan 2021 00:19:46 +0800</pubDate></item></channel></rss>